Lantern Pharma Inc. 2025 Q4 - Results - Earnings Call Presentation

Lantern Pharma released its Q4 2025 earnings presentation during a March 2026 earnings call, detailing financial performance and operational milestones for the biotech firm specializing in AI-driven drug discovery. The slide deck highlights key financial metrics, including revenue growth, R&D expenditures, and pipeline progress, though specific figures remain undisclosed in the transcript summary. Company leadership emphasized advancements in quantum computing-enhanced drug development, signaling deeper integration of AI and quantum algorithms to accelerate precision oncology therapies. Investor updates included regulatory timelines for lead candidates, with potential FDA submissions expected in 2026–2027, pending clinical trial outcomes. The presentation underscored Lantern’s strategic shift toward quantum-optimized computational biology, positioning it as a frontrunner in next-gen pharmaceutical innovation.